Barry R. Davies
YOU?
Author Swipe
View article: Supplementary Table S2 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
Supplementary Table S2 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control Open
Growth Rate
View article: Data from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
Data from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control Open
Purpose:Combining radiotherapy (RT) with DNA damage response inhibitors may lead to increased tumor cell death through radiosensitization. DNA-dependent protein kinase (DNA-PK) plays an important role in DNA double-strand break repair via …
View article: Supplementary Figure 1-9 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
Supplementary Figure 1-9 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control Open
Supplementary Figure 1-9
View article: Supplementary Figure Legends from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
Supplementary Figure Legends from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control Open
Supplementary Figure Legends
View article: Supplementary Table S1 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
Supplementary Table S1 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control Open
Plating Efficiency
View article: Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration Open
View article: MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells Open
View article: 43P AKT and estrogen receptor (ER) inhibition potently impairs endocrine resistance (EndoR) in breast cancer (BC)
43P AKT and estrogen receptor (ER) inhibition potently impairs endocrine resistance (EndoR) in breast cancer (BC) Open
The PI3K/AKT/mTOR and MEK/MAPK pathways are suggested mechanisms of EndoR. However, single kinase inhibitors (Ki), like everolimus, only partially reverse EndoR, probably due to activation of adaptive pathways. We previously showed that co…
View article: Supplementary Figure 3 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Supplementary Figure 3 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background Open
PDF file - 84K, Correlation of AZD5363 activity in cell lines from different tumor types with RAS, PIK3CA and PTEN status.
View article: supplementary Table 4 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 4 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Differential gene expression and statistical analysis of cell lines treated with AZD4547 or DMSO over time
View article: Data from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
Data from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
The challenge of developing effective pharmacodynamic biomarkers for preclinical and clinical testing of FGFR signaling inhibition is significant. Assays that rely on the measurement of phospho-protein epitopes can be limited by the availa…
View article: supplementary Table 2 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 2 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
55 FGFR2 modified dynamic biomarker after treatment by AZD4547
View article: Supplementary Figure 5 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Supplementary Figure 5 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background Open
PDF file - 88K, Quantification of cleaved caspase 3 activity in HCC-1187 xenografts following chronic dosing with 5 mg/kg once weekly docetaxel (taxotere), 150 mg/kg bid AZD5363, or a combination of these two agents.
View article: Supplementary figure 3 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER<sup>+</sup> Breast Cancer When Administered Using Intermittent or Continuous Schedules
Supplementary figure 3 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER<sup>+</sup> Breast Cancer When Administered Using Intermittent or Continuous Schedules Open
Pharmacokinetics modelling of AZD2014 intermittent dosing schedule.
View article: Supplementary Table 1 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Supplementary Table 1 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background Open
XLS file - 82K, Details of cell lines.
View article: Supplementary figure 1 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER<sup>+</sup> Breast Cancer When Administered Using Intermittent or Continuous Schedules
Supplementary figure 1 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER<sup>+</sup> Breast Cancer When Administered Using Intermittent or Continuous Schedules Open
HCC1428-eveR and HCC1428-LTED-eveR cell lines resistant to everolimus remain sensitive to dual mTORC1/2 inhibitor AZD2014.
View article: Supplementary Figure 4 from Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression <i>In Vivo</i>
Supplementary Figure 4 from Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression <i>In Vivo</i> Open
PDF - 132KB, Effect of AZD5363 on nuclear translocation of AR
View article: Supplementary figures from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
Supplementary figures from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Supplementary figures S1: volcano plot of insensitive cell lines treated by AZD4547 S2:Immunohistochemistry of p-S6 and p-ERK tissue sections from xenograft treated with AZD4547 S3:FGFR pathway modulation in xenograft models treated with A…
View article: supplementary Table1 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table1 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Cell line panel used to identify AZD4547 dynamic transcript biomarkers.
View article: S5. Validation of target genes within pathways shown to be up-regulated by AZD5363 treatment. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) <i>In Vivo</i>
S5. Validation of target genes within pathways shown to be up-regulated by AZD5363 treatment. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) <i>In Vivo</i> Open
MCF7 and MCF7-LTED cells lines were cultured in DCC {plus minus} AZD5363 and mRNA analysis performed by RT-qPCR. Error bars represent {plus minus} SEM. *p<0.05; **p<0.01; ***p<0.001. Coloured dots indicate which signalling pathways each ge…
View article: Data from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) <i>In Vivo</i>
Data from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) <i>In Vivo</i> Open
PI3K/AKT/mTOR signaling plays an important role in breast cancer. Its interaction with estrogen receptor (ER) signaling becomes more complex and interdependent with acquired endocrine resistance. Targeting mTOR combined with endocrine ther…
View article: supplementary Table 5 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 5 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Statistical analysis of gene modulation between FGFR1, 2 and 3 dysregulated cell lines.
View article: Supplementary Figure 5 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Supplementary Figure 5 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background Open
PDF file - 88K, Quantification of cleaved caspase 3 activity in HCC-1187 xenografts following chronic dosing with 5 mg/kg once weekly docetaxel (taxotere), 150 mg/kg bid AZD5363, or a combination of these two agents.
View article: Supplementary Figure 1 from Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression <i>In Vivo</i>
Supplementary Figure 1 from Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression <i>In Vivo</i> Open
PDF - 67KB, Cartoon showing development of CRPC and treatment regime
View article: Supplementary Figure 2 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Supplementary Figure 2 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background Open
PDF file - 81K, Correlation of AZD5363 activity in cell lines from different tumor types with PIK3CA and PTEN mutation status.
View article: Supplemenary Figure 2 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER<sup>+</sup> Breast Cancer When Administered Using Intermittent or Continuous Schedules
Supplemenary Figure 2 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER<sup>+</sup> Breast Cancer When Administered Using Intermittent or Continuous Schedules Open
Pharmacokinetics and PK/PD relationships for AZD2014
View article: Supplementary Materials text from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Supplementary Materials text from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel Open
Supplementary Materials text. Supplementary text to support supplementary data.
View article: Supplementary Tables 1-3 and Figure 1-7 from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Supplementary Tables 1-3 and Figure 1-7 from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel Open
Supplementary Tables 1-3 and Figure 1-7. Supp Table 1 Summary of cell line origins and verification. Supp Table 2 Summary of antibodies used in all experimental analysis Supp Fig 1 AZD8186 inhibits PI3K pathway in PTEN null but not PTEN WT…
View article: Supplementary Figure 4 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Supplementary Figure 4 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background Open
PDF file - 139K, AZD5363 has a predominantly anti-proliferative mechanism of action but induces cell death in BT474c, LNCaP and PC346C-Flut1 cells in vitro, and in BT474c xenografts following a high, intermittent dosing schedule in vivo.
View article: Supplementary Materials text from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Supplementary Materials text from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel Open
Supplementary Materials text. Supplementary text to support supplementary data.